Whitehawk Therapeutics (NASDAQ:WHWK) Insider Sells $336,554.40 in Stock

Whitehawk Therapeutics, Inc. (NASDAQ:WHWK) insider Bryan Ball sold 92,460 shares of Whitehawk Therapeutics stock in a transaction on Tuesday, April 14th. The shares were sold at an average price of $3.64, for a total value of $336,554.40. Following the completion of the transaction, the insider owned 397,106 shares of the company’s stock, valued at approximately $1,445,465.84. This trade represents a 18.89% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Bryan Ball also recently made the following trade(s):

• On Monday, April 13th, Bryan Ball sold 26,389 shares of Whitehawk Therapeutics stock. The shares were sold at an average price of $3.46, for a total value of $91,305.94.
• On Friday, April 10th, Bryan Ball sold 6,596 shares of Whitehawk Therapeutics stock. The shares were sold at an average price of $3.43, for a total value of $22,624.28.
• On Thursday, April 9th, Bryan Ball sold 50,000 shares of Whitehawk Therapeutics stock. The shares were sold at an average price of $3.57, for a total value of $178,500.00.
• On Monday, March 2nd, Bryan Ball sold 1,834 shares of Whitehawk Therapeutics stock. The shares were sold at an average price of $3.31, for a total value of $6,070.54.

Whitehawk Therapeutics Trading Down 2.8%

NASDAQ:WHWK opened at $4.11 on Friday. The firm has a market cap of $193.99 million, a PE ratio of 8.74 and a beta of 0.57. The stock has a fifty day moving average price of $3.46 and a 200 day moving average price of $2.78. Whitehawk Therapeutics, Inc. has a 12-month low of $1.39 and a 12-month high of $4.48.

Whitehawk Therapeutics (NASDAQ:WHWK) last released its earnings results on Thursday, March 12th. The company reported ($0.34) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.55) by $0.21.

Wall Street Analyst Weigh In

A number of analysts have issued reports on WHWK shares. JonesTrading started coverage on Whitehawk Therapeutics in a report on Monday, December 22nd. They set a “buy” rating and a $7.00 price target for the company. Wall Street Zen downgraded Whitehawk Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, April 11th. Citigroup started coverage on Whitehawk Therapeutics in a report on Thursday. They set an “outperform” rating for the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Whitehawk Therapeutics in a report on Friday, March 27th. Finally, Oppenheimer started coverage on Whitehawk Therapeutics in a report on Thursday, February 5th. They set an “outperform” rating and a $6.00 price target for the company. Four investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $7.00.

Institutional Trading of Whitehawk Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the company. Quadrature Capital Ltd acquired a new position in Whitehawk Therapeutics in the 4th quarter valued at about $28,000. ABG Innovation Capital Partners III GP Ltd acquired a new position in Whitehawk Therapeutics in the 3rd quarter valued at about $51,000. Dimensional Fund Advisors LP acquired a new position in Whitehawk Therapeutics in the 3rd quarter valued at about $84,000. Squarepoint Ops LLC acquired a new position in Whitehawk Therapeutics in the 3rd quarter valued at about $159,000. Finally, Marshall Wace LLP acquired a new position in Whitehawk Therapeutics in the 4th quarter valued at about $164,000. 52.08% of the stock is owned by hedge funds and other institutional investors.

More Whitehawk Therapeutics News

Here are the key news stories impacting Whitehawk Therapeutics this week:

• Positive Sentiment: Citizens/JMP initiated coverage with a “Market Outperform” and an $8.00 price target (roughly ~95% above recent levels), a catalyst that has supported buying interest ahead of impending trial data. Citizens Outperform
• Neutral Sentiment: Whitehawk’s CEO will appear in a Jones Trading Post–AACR virtual fireside chat on April 23 — a visibility event that can help inform investors but is unlikely to move the stock by itself. Fireside Chat
• Neutral Sentiment: Institutional ownership is meaningful (~52%) and coverage is mixed: a consensus “Hold” with an average target near $6.50 (some firms bullish, others negative), so analyst views are a mixed influence on price. Institutional Holdings
• Negative Sentiment: Significant insider selling this week — CFO Scott Giacobello sold 141,600 shares (4/16) and 77,000 shares (4/15) and director/officer Bryan Ball sold multiple blocks — has increased supply and likely pressured the stock. Company disclosures say the sales were to cover tax withholding on vested awards, but the size and frequency of sales reduced insiders’ stakes materially. SEC filings: CFO Form 4 and Other Insider Forms

Whitehawk Therapeutics Company Profile

Aadi Bioscience, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway. The company was incorporated in 2007 and is headquartered in Pacific Palisades, California.